Ether Oxygen Single Bonded To Carboxylic Acid, Percarboxylic Acid Or Salt Thereof Through An Acyclic Carbon Or Acyclic Carbon Chain Patents (Class 514/571)
-
Patent number: 8722083Abstract: Various fenofibrate compositions include a plurality of first granules having a high bioavailability in vivo, and a plurality of second granules having a low bioavailability in vivo. The first granules may comprise fenofibrate, from 0.3% to 10% by weight of the first granules of a first surfactant, and a first water soluble or water dispersible cellulose derivative, and the second granules may comprise fenofibrate, from 0% to 0.25% by weight of the second granules of a second surfactant, and a second water soluble or water dispersible cellulose derivative.Type: GrantFiled: June 25, 2012Date of Patent: May 13, 2014Assignee: Mylan, Inc.Inventors: Sarat C. Chattaraj, Glenn Allen Redelman, Andrew Alan Shaw
-
Publication number: 20140128354Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.Type: ApplicationFiled: January 14, 2014Publication date: May 8, 2014Applicant: BIOCOPEA LIMITEDInventors: Robin M. Bannister, John Brew
-
Publication number: 20140128439Abstract: Methods of treating gout flares comprising administering a composition comprising a first urate-lowering agent are disclosed. In some aspects, the first urate-lowering agent is (?)-halofenate, (?)-halofenic acid, or a pharmaceutically acceptable salt thereof. Other aspects provide for methods of reducing the number, duration, frequency or intensity of gout flares experienced by a subject.Type: ApplicationFiled: August 7, 2013Publication date: May 8, 2014Applicant: Metabolex, Inc.Inventors: Brian Edward Lavan, Gopal Chandra Saha, Brian K. Roberts, Charles A. McWerther
-
Publication number: 20140128473Abstract: A compound of Formula (I): or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, X1 and X2 are as defined herein, is useful for treating non-alcoholic steatohepatitis (NASH) and/or reducing one or more of hepatic fibrosis, lobular inflammation, and hepatocellular ballooning.Type: ApplicationFiled: January 10, 2014Publication date: May 8, 2014Applicant: MediciNova, Inc.Inventor: Kazuko MATSUDA
-
Publication number: 20140128438Abstract: Methods of treating gout flares comprising administering a composition comprising a first urate-lowering agent are disclosed. In some aspects, the first urate-lowering agent is (?)-halofenate, (?)-halofenic acid, or a pharmaceutically acceptable salt thereof. Other aspects provide for methods of reducing the number, duration, frequency or intensity of gout flares experienced by a subject.Type: ApplicationFiled: November 2, 2012Publication date: May 8, 2014Inventors: Brian Edward Lavan, Gopal Chandra Saha, Charles A. McWherter, Brian K. Roberts
-
Publication number: 20140113948Abstract: The present specification discloses compositions comprising a pharmaceutical composition to reduce or maintain LDL and/or cholesterol levels in an individual and a plurality of therapeutic compounds to increase or maintain HDL levels in an individual. The present specification also discloses a treatment protocol wherein a pharmaceutical composition is administered to an individual on a schedule wherein the pharmaceutical composition is provided for a period of time and then not provided to the individual and this treatment protocol is repeated for the term of the individual's treatment.Type: ApplicationFiled: October 24, 2013Publication date: April 24, 2014Applicant: BIOCOPEA LIMITEDInventors: John Brew, Robin Mark Bannister
-
Patent number: 8703821Abstract: The present invention provides dialkyl ether compounds and pharmaceutically acceptable salts thereof, compositions containing the same and one or more active agents, and methods of administering active agents with the same.Type: GrantFiled: April 18, 2007Date of Patent: April 22, 2014Assignee: Emisphere Technologies Inc.Inventor: Jianfeng Song
-
Patent number: 8703202Abstract: Disclosed is a pharmaceutically acceptable oral dosage form comprising fenofibrate, phospholipid, a buffer salt, a water-soluble bulking agent selected from maltodextrin, mannitol, and combinations thereof, a cellulosic additive, beads or crystals of a pharmaceutically acceptable water-soluble excipient support material, a polyvinylpyrrolidone or crospovidone, croscarmellose sodium, granular mannitol, sodium dodecyl sulfate, silicon dioxide, and a stearate, wherein the fenofibrate is in the form of microparticles, and wherein at least a portion of the phospholipid is coated on the surfaces of the fenofibrate microparticles, the phospholipid coated microparticles are embedded in a matrix comprising the water-soluble bulking agent, phospholipid that is not coated on the microparticles, the buffer salt and the cellulosic additive, and the matrix is coated on up to 100% of the surfaces of the beads or crystals of the excipient support material.Type: GrantFiled: July 24, 2006Date of Patent: April 22, 2014Assignee: Jagotec AGInventors: Michael Vachon, Mishra K. Awadhesh, Robert A. Snow, Pol-Henri Guivarc'h
-
Patent number: 8673819Abstract: The present invention teaches a surfactant blend composition of at least one nonionic alkoxylate and at least one sugar-based surfactant, and its use as an adjuvant for pesticides. The pesticidal composition employing the surfactant blend composition of the invention realizes an efficacy that is unexpectedly superior to similar pesticidal compositions which employ only the individual surfactant components. The composition of the present invention is useful as a tank side additive, or as a component in herbicidal formulations. In addition the compositions of the present invention are useful as adjuvants for other pesticides, such as, fungicides, insecticides, plant growth regulators, acaracides and the like.Type: GrantFiled: July 3, 2009Date of Patent: March 18, 2014Assignee: Akzo Nobel N.V.Inventor: Jinxia Susan Sun
-
Patent number: 8663693Abstract: Nanoparticles and nanoparticle formulations or suspensions are provided which comprise a fibrate and vitamin E TPGS. The nanoparticles may have a mean diameter, measured by photon correlation spectroscopy, in the range of from about 100 nm to about 900 nm. Pharmaceutical formulations and uses of such compositions are also provided.Type: GrantFiled: August 9, 2002Date of Patent: March 4, 2014Assignee: Jagotec AGInventors: Pascal Grenier, Guy Vergnault, Alain Nhamias
-
Publication number: 20140044668Abstract: Methods and compositions for the effect of Cholesteryl ester transfer protein (CETP) polymorphisms on mRNA splicing, statin treatment outcome, response to CETP inhibitor drugs, and myocardial infarction risk are described.Type: ApplicationFiled: February 15, 2012Publication date: February 13, 2014Applicant: THE OHIO STATE UNIVERSITYInventors: Wolfgang Sadee, Audrey C. Papp
-
Publication number: 20140017329Abstract: A composition and an associated method for hepatic targeted delivery of thyroid receptor beta1 (TR?1) agonist to a liver of a subject. The composition includes hydrophobic nanoparticles, a liver targeting moiety exterior to each nanoparticle and covalently bonded to each nanoparticle, and at least one TR?1 agonist encapsulated within each nanoparticle. The nanoparticles include chitosan hybrid nanoparticles, amine-modified PLGA nanoparticles, solid lipid nanoparticles, and combinations thereof. The liver targeting moiety includes Glycyrrhetinic acid (GA), Lactobionic acid (LA), or combinations thereof.Type: ApplicationFiled: July 10, 2013Publication date: January 16, 2014Inventor: Shaker A. Mousa
-
Publication number: 20140005052Abstract: Phytosanitary compositions in the form of microemulsions with active ingredients formulated in their acid form, with compositions comprising a combination of an active ingredient or mixtures thereof in their acid form, a non-ionic surfactant, an anionic surfactant, a polar cosolvent, and water.Type: ApplicationFiled: June 28, 2012Publication date: January 2, 2014Applicant: Red Surcos S.A.Inventor: Edmundo Blumel
-
Publication number: 20130344155Abstract: Various fenofibrate compositions include a plurality of first granules having a high bioavailability in vivo, and a plurality of second granules having a low bioavailability in vivo. The first granules may comprise fenofibrate, from 0.3% to 10% by weight of the first granules of a first surfactant, and a first water soluble or water dispersible cellulose derivative, and the second granules may comprise fenofibrate, from 0% to 0.25% by weight of the second granules of a second surfactant, and a second water soluble or water dispersible cellulose derivative.Type: ApplicationFiled: June 25, 2012Publication date: December 26, 2013Applicant: MYLAN, INC.Inventors: Sarat C. CHATTARAJ, Glenn Allen Redelman, Andrew Alan Shaw
-
Publication number: 20130331453Abstract: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.Type: ApplicationFiled: August 14, 2013Publication date: December 12, 2013Applicant: Janssen Pharmaceutica NVInventors: Gee-Hong Kuo, Rui Zhang, Aihua Wang, Alan R. DeAngelis
-
Patent number: 8580854Abstract: Accelerated formation of advanced glycation/lipoxidation end products (AGEs/ALEs) has been implicated in the pathogenesis of various diabetic complications. Several natural and synthetic compounds have been proposed and tested as inhibitors of AGE/ALE formation. We have previously reported the therapeutic effects of several new AGE/ALE inhibitors on the prevention of nephropathy and dyslipidemia in streptozotocin (STZ)-induced diabetic rats. In this study, we investigated the effects of various concentrations of LR-90 on the progression of renal disease and its effects on AGE and receptor for AGE (RAGE) protein expression on the kidneys of diabetic STZ-rats. In vitro studies were also performed to determine if LR-90 could inhibit the expression of various pro-inflammatory mediators in human monocytic cells.Type: GrantFiled: November 9, 2006Date of Patent: November 12, 2013Assignee: City of HopeInventors: Samuel Rahbar, Rama Natarajan
-
Publication number: 20130295185Abstract: A novel BH3 ?-helical mimetic, BH3-M6, which binds to Bcl-XL and prevents its binding to fluorescently-labeled Bak-BH3 peptide in vitro with an IC50 value of 734 nM is presented herein. BH3-M6 is a pan-Bcl-2 antagonist that inhibits the binding of Bcl-XL, Bcl-2 and Mcl-1 to multi-domain Bax or Bak, or BH3-only Bim or Bad in a cell-free system and in intact human cancer cells, freeing up pro-apoptotic proteins to induce apoptosis. BH3-M6-induced apoptosis is caspase- and Bax-dependent. Furthermore, human cancer cells with high Bcl-2 or Bcl-XL levels are more sensitive to BH3-M6-induced cell death, suggesting that this compound can overcome drug resistance due to Bcl-2 or Bcl-XL overexpression. The pan-Bcl-2 inhibitor BH3-M6 may be encapsulated in a micelle to provide a more bioavailable therapeutic agent. Specifically, the BH3-M6 compound may be encapsulated within a micelle comprising a multiblock copolymer according to the methods described herein.Type: ApplicationFiled: July 12, 2013Publication date: November 7, 2013Inventors: Said M. Sebti, Andrew D. Hamilton, Kevin Sill, Adam Carie
-
Publication number: 20130251664Abstract: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.Type: ApplicationFiled: March 8, 2013Publication date: September 26, 2013Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventor: Richard T. Lee
-
Patent number: 8541456Abstract: The application relates to specific combinations of Roflumilast and/or Roflumilast N-Oxide and a PPAR-agonist, as well as their use in the treatment of diabetes mellitus type 2.Type: GrantFiled: July 11, 2011Date of Patent: September 24, 2013Assignee: Takeda GmbHInventors: Hans-Peter Kley, Guido Hanauer, Daniela Hauser, Beate Schmidt, Dirk Bredenbröker, Wilhelm Wurst, Jörg Kemkowski
-
Publication number: 20130225681Abstract: Phenylketone carboxylate compounds of Formula I, wherein n=2-6; R?C(0); —OC(O)— or —CH(OH)—; A is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when B is Ft B is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when A is Ft or A and B form a 5-7 membered cycloalkyl substituted with COOFt W=0, S or NFt Y=0,S,NH or CH2; m=0-2; p=1-7; have been prepared. These compounds and their pharmaceutically acceptable salts have beneficial therapeutic effects to prevent or treat a condition related to (l) blood disorders, (ii) inflammation related diseases, (iii) renal disorders and/or renal disorders complications, or (iv) fibrosis-related organ dysfunction.Type: ApplicationFiled: October 26, 2011Publication date: August 29, 2013Applicant: PROMETIC BIOSCIENCES INC.Inventors: Boulos Zacharie, Christopher Penney, Shaun Abbott, Lyne Gagnon, Brigette Grouix, Pierre Laurin
-
Publication number: 20130225683Abstract: New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I, Formula I, IA, IB and IC, and their pharmaceutical acceptable salts are described for prevention or treatment of diabetes or a diabetes-related disorder in a subject in need thereof. Diabetes and diabetes-related disorder include Type I diabetes, Type II diabetes, maturity-onset diabetes of the young, latent autoimmune diabetes of adults (LADA), gestational diabetes, diabetic nephropathy, proteinuria, ketonuria, obesity, hyperglycemia, glucose intolerance, insulin resistance, hyperinsulinemia, hypercholesterolemia, hypertension, hyperlipoproteinemia, hyperlipidemia, hypertriglyceridemia, dyslipidemia, metabolic syndrome, syndrome X, diabetic neuropathy, diabetic retinopathy, hypoglycemia, cardiovascular disease, atherosclerosis, diabetic kidney disease, ketoacidosis, thrombotic disorders, sexual dysfunction, dermatopathy, edema, metabolic syndrome and renal disorders.Type: ApplicationFiled: October 26, 2011Publication date: August 29, 2013Applicant: PROMETIC BIOSCIENCES INC.Inventors: Lyne Gagnon, Brigette Grouix, Pierre Laurin
-
Patent number: 8518997Abstract: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.Type: GrantFiled: December 21, 2011Date of Patent: August 27, 2013Assignee: Janssen Pharmaceutica N.V.Inventors: Gee-Hong Kuo, Rui Zhang, Aihua Wang, Alan R. DeAngelis
-
Publication number: 20130165453Abstract: The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or other neurotrophic factors to treat stroke. Specifically, the present invention provides methods of treating stroke comprising the steps of identifying a subject having suffered a stroke and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of stroke.Type: ApplicationFiled: July 19, 2012Publication date: June 27, 2013Inventors: Miao-Kun Sun, Daniel L. Alkon
-
Publication number: 20130158123Abstract: A compound of Formula (I): or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, X1 and X2 are as defined herein, is useful for treating non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).Type: ApplicationFiled: December 5, 2012Publication date: June 20, 2013Applicant: MediciNova, Inc.Inventor: MediciNova, Inc.
-
Publication number: 20130142858Abstract: Drug delivery devices comprising a non-bioabsorbable polymer structure configured to support a composition comprising an active agent. The devices include a plurality of portions fused together and a recess configured to support the composition. At least one of the portions includes an impermeable polymer and at least one other portion includes a rate-limiting water-permeable polymer. The rate-limiting water-permeable polymer allows for transportation of the active agent to an exterior of the device.Type: ApplicationFiled: May 17, 2011Publication date: June 6, 2013Applicant: Aerie Pharmaceuticals, Inc.Inventors: Casey Kopczynski, Cheng-Wen Lin, Chris Sutay
-
Patent number: 8450371Abstract: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.Type: GrantFiled: August 29, 2012Date of Patent: May 28, 2013Assignee: Janssen Pharmaceutica, N.V.Inventors: Gee-Hong Kuo, Rui Zhang, Aihua Wang, Alan R. DeAngelis
-
Publication number: 20130101553Abstract: Provided are methods of treating fibrotic conditions in a subject and diagnostic methods for determining fibrosis and appropriate treatments for the fibrosis by the identification of specific subsets of fibrogenic myofibroblasts.Type: ApplicationFiled: April 18, 2012Publication date: April 25, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Tatiana KISSELEVA, David BRENNER
-
Patent number: 8415394Abstract: The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.Type: GrantFiled: December 21, 2011Date of Patent: April 9, 2013Assignee: Astrazeneca ABInventors: Timothy Jon Luker, Rukhsana Tanseem Mohammed, Mark Dickinson, Stephen Thom
-
Publication number: 20130085181Abstract: The present invention provides a modified release formulation comprising an active agent in a hydrophilic polymer matrix wherein the active agent is a salt of fenofibric acid wherein the release rate of the formulation in an in vitro dissolution is substantially independent of the ionic strength of the dissolution media.Type: ApplicationFiled: May 31, 2012Publication date: April 4, 2013Inventors: Yi Gao, Tzuchi R. Ju, Dennis Y. Lee, Nicole Nguyen, Huailiang Wu
-
Patent number: 8377994Abstract: The use of Schülpen based on pyrogenically produced silicon dioxide in pharmaceutical compositions is described.Type: GrantFiled: May 10, 2006Date of Patent: February 19, 2013Assignee: Evonik Degussa GmeHInventors: Ann Gray, Margarete Drechsler, Ralph Hofmann
-
Publication number: 20130040991Abstract: The invention provides gemfibrozil for use in adjusting the effect of a CYP2C8 and/or OATP substrate drug, wherein gemfibrozil is administered in an amount of less than 1200 mg/day. The invention also provided a pharmaceutical composition comprising gemfibrozil providing a significant improvement to the plasma profiles of a CYP2C8 and/or OATP substrate drug in a mammal.Type: ApplicationFiled: March 29, 2011Publication date: February 14, 2013Inventors: Pertti Neuvonen, Mikko Niemi, Janne Backman
-
Publication number: 20130022684Abstract: An oral pharmaceutical composition of the present invention comprising fenofibric acid or a pharmaceutically acceptable salt thereof, and 0.22 to 1 part by weight of an alkalifying agent based on 1 part by weight of fenofibric acid has improved bioavailability and a minimized absorption deviation in the gastrointestinal tract, which is useful in treating hyperlipidemia and hypertriglyceridemia.Type: ApplicationFiled: April 12, 2011Publication date: January 24, 2013Applicant: HANMI SCIENCE CO., LTD.Inventors: Ki Young Jang, Mijin Park, Kyeong Soo Kim, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
-
Publication number: 20130018101Abstract: In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.Type: ApplicationFiled: September 14, 2012Publication date: January 17, 2013Inventors: Russell Drew Cink, Joseph B. Paterson, JR., Yi Gao, Geoff G. Z. Zhang, Michelle A. Long, John B. Morris, Joerg Rosenberg
-
Patent number: 8349897Abstract: The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.Type: GrantFiled: December 20, 2010Date of Patent: January 8, 2013Assignee: Astrazeneca ABInventors: Timothy Jon Luker, Rukhsana Tanseem Mohammed, Mark Dickinson, Stephen Thom
-
Publication number: 20120322875Abstract: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.Type: ApplicationFiled: August 29, 2012Publication date: December 20, 2012Inventors: Gee-Hong Kuo, Rui Zhang, Aihua Wang, Alan R. DeAngelis
-
Publication number: 20120322769Abstract: A method of reducing virulence in a bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a compound described herein.Type: ApplicationFiled: February 16, 2011Publication date: December 20, 2012Applicants: DUKE UNIVERSITY, UWM RESEARCH FOUNDATIONInventors: Ching-Hong Yang, Xin Chen, Eric J. Toone
-
Publication number: 20120295981Abstract: Tetrasubstituted benzenes that act as modulators of gamma secretase and their use in the treatment of one or more symptoms of treating neurodegenerative disorders, e.g., Alzheimer's disease, are described.Type: ApplicationFiled: June 1, 2012Publication date: November 22, 2012Applicant: EnVivo PHARMACEUTICALS, INC.Inventors: Gideon SHAPIRO, Richard CHESWORTH
-
Publication number: 20120289402Abstract: An adjuvant composition is provided which comprises: (a) at least one water-soluble electrolyte; (b) at least one electrolyte-tolerant surfactant; (c) antifoam component which is at least one mixture selected from the group consisting of (1) at least one branched silicone resin (i), at least one silicone fluid (ii), at least one particulate metal oxide (iii) and, optionally, at least one catalyst (iv) for catalyzing the condensation of siloxy groups, (2) the equilibration reaction product of mixture (1), and (3) mixture (1) in which at least a portion of particulate metal oxide (iii) is pre-hydrophobized; (d) optionally, at least one additional bioinert material; and, (e) water.Type: ApplicationFiled: May 9, 2011Publication date: November 15, 2012Applicant: Momentive Performance Materials Inc.Inventors: William L. Brown, Kalman Koczo, George A. Policello
-
Publication number: 20120270845Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.Type: ApplicationFiled: February 3, 2012Publication date: October 25, 2012Inventors: Robin Mark Bannister, John Brew, Wilson Caparros-Wanderley, Gregory Alan Stoloff, Suzanne Jane Dilly, Gemma Szucs, Olga Pleguezuelos Mateo
-
Publication number: 20120270899Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions.Type: ApplicationFiled: February 3, 2012Publication date: October 25, 2012Inventors: Robin Mark Bannister, John Brew, Suzanne Jane Dilly, Gregory Alan Stoloff, Wilson Caparros-Wanderley
-
Publication number: 20120252725Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as amino-transferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.Type: ApplicationFiled: November 26, 2010Publication date: October 4, 2012Inventors: Raphaël Darteil, Rémy Hanf, Dean Hum
-
Publication number: 20120245213Abstract: Methods and compositions are provided for modulating the activity of human type I taste receptor subunit 3 (hT1R3). Such materials and methods are useful for the screening and preparation of compositions and methods for the treatment of carbohydrate and lipid metabolic diseases and disorders.Type: ApplicationFiled: October 1, 2010Publication date: September 27, 2012Inventors: Bedrich Mosinger, Emeline Maillet, Robert Margolskee
-
Publication number: 20120225946Abstract: Described are solid pharmaceutical compositions for oral administration comprising choline fenofibrate and an amount of an acid sufficient to substantially reduce a rate of dissolution of choline fenofibrate in an aqueous environment at pH 4.5 to less than about 50% in 2 hours. Processes for making the solid pharmaceutical composition for oral administration comprising: (a) mixing choline fenofibrate with an amount of an acid sufficient to substantially reduce a rate of dissolution of choline fenofibrate in an aqueous environment at pH 4.5 to less than about 50% in 2 hours; and (b) preparing a dosage form suitable for oral administration are also provided.Type: ApplicationFiled: September 9, 2010Publication date: September 6, 2012Inventor: Bernard Charles Sherman
-
Patent number: 8258177Abstract: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.Type: GrantFiled: August 11, 2011Date of Patent: September 4, 2012Assignee: Janssen Pharmaceutica, N.V.Inventors: Gee-Hong Kuo, Rui Zhang, Aihua Wang, Alan R. DeAngelis
-
Patent number: 8252840Abstract: This present invention provides methods and pharmaceutical compositions for the treatment or prophylaxis of diabetes and related disorders, comprising the administration of an effective amount of a monoester of probucol, particularly the monosuccinic acid ester, or a pharmaceutically acceptable salt or derivative thereof.Type: GrantFiled: March 26, 2008Date of Patent: August 28, 2012Assignee: Salutria Pharmaceuticals LLCInventor: Robert A. D. Scott
-
Patent number: 8247448Abstract: The present invention relates to butenoic acid derivatives of the formula I: in which R, R1, R2 and R3 are as defined in the description, and also to processes for the preparation thereof, to pharmaceutical compositions comprising them and to their use for the treatment of dyslipidaemia, atherosclerosis and diabetes.Type: GrantFiled: June 23, 2010Date of Patent: August 21, 2012Assignee: Merck Patent GmbHInventors: Jean-Jacques Zeiller, Hervé Dumas, Valérie Guyard-Dangremont, Isabelle Berard, Francis Contard, Daniel Guerrier, Gérard Ferrand, Yves Bonhomme
-
Patent number: 8242173Abstract: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia.Type: GrantFiled: September 1, 2010Date of Patent: August 14, 2012Assignee: Janssen Pharmaceutica N.V.Inventors: Alan DeAngelis, Keith T Demarest, Gee-Hong Kuo, Patricia Pelton, Aihua Wang, Rui Zhang
-
Publication number: 20120178808Abstract: A formulation comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients is described. Fenofibric acid, the physiologically acceptable salt or derivative thereof is preferably in the form of a molecular dispersion in these formulations. An advantageous process for their preparation, in particular by melt extrusion, and the use of this formulation for oral administration of fenofibric acid, a physiologically acceptable salt or derivative thereof are likewise described.Type: ApplicationFiled: March 15, 2012Publication date: July 12, 2012Inventors: Joerg Rosenberg, Matthias Degenhardt, Joerg Breitenbach, Tom L. Reiland, Kennan C. Marsh
-
Publication number: 20120178814Abstract: The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.Type: ApplicationFiled: December 21, 2011Publication date: July 12, 2012Inventors: Timothy Jon Luker, Rukhsana Tanseem Mohammed, Mark Dickinson, Stephen Thom
-
Patent number: 8188148Abstract: The present invention concerns substituted 1,3-diphenylpropane derivatives, pharmaceutical compositions comprising them and the therapeutic uses thereof, particularly in the field of human and animal health.Type: GrantFiled: June 21, 2007Date of Patent: May 29, 2012Assignee: GenfitInventors: Jean-François Delhomel, Rémy Hanf, Karine Caumont-Bertrand